Small-molecule therapies can stop viral replication following infection, and our study proposes that vicenin-2, neohesperidin, naringin, and rhoifolin can act as TMPRSS2 antagonists and viral entry inhibitors, subject to experimental validations. The gene discussed is TMPRSS2; the disease is infection.